Biological Warfare Agents, Communicable Diseases, Disease Outbreaks, Emerging Infectious Diseases, Zoonoses
Conditions
Keywords
Blood and blood derivatives: whole blood, serum, plasma, cord blood, Microbiological specimens: positive blood cultures, Urine samples, Respiratory samples, expectorations, bronchoalveolar lavage (BAL), protected distal samples, bronchial aspirations, Cerebrospinal fluid, Stool or rectal swabs, Skin or mucosal swabs, Biopsies and puncture material: lymph node, hepatic, gastric, or other tissue samples when available
Brief summary
This multicenter prospective registry aims to establish a biobank of residual biological samples and associated clinical data from hospitalized patients. The registry will collect a wide range of specimens (serum, plasma, respiratory samples, urine, cerebrospinal fluid, biopsies) obtained during routine care, without any additional procedures. Data are pseudonymized and stored securely for up to 20 years. The biobank will be used to develop and evaluate rapid diagnostic tests (RDTs) for emerging infectious diseases and CBRN threats to improve epidemic preparedness and patient management.
Detailed description
The DiagRaMIE Biobank is designed to support the national strategy for emerging infectious diseases and CBRN (Chemical, Biological, Radiological, Nuclear) threats. Over a 3-year inclusion period, residual samples from routine care (e.g., blood, plasma, urine, cerebrospinal fluid, respiratory specimens, biopsies) will be systematically collected from eligible hospitalized patients in Bicêtre and Paul Brousse hospitals. Associated demographic, clinical, and microbiological data will be recorded in a secure electronic case report form (eCRF) and pseudonymized. No additional procedures, visits, or interventions are required for participants. The biobank will provide a sustainable source of high-quality biological material and standardized data to enable the development, validation, and rapid deployment of in vitro rapid diagnostic tests (RDTs) targeting pathogens of major public health concern, including those prioritized by WHO (e.g., Yersinia pestis, Candida auris, Francisella tularensis, MERS-CoV, Nipah virus, Crimean-Congo hemorrhagic fever virus). This initiative aims to strengthen epidemic surveillance and preparedness and to ensure timely diagnostic capacity in future public health crises.
Interventions
None listed
Sponsors
Assistance Publique - Hôpitaux de Paris
NG Biotech
Commissariat A L'energie Atomique
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults (≥ 18 years old) hospitalized in one of the participating centers at Bicêtre or Paul Brousse hospitals, for whom residual biological samples are available as part of routine care in one or more participating hospital departments. * Covered by, or entitled to, the French social security system (excluding State Medical Aid - AME). * Patient or legal representative/trusted person informed about the registry and having provided written consent to participate.
Exclusion criteria
* Patients under judicial protection (guardianship or curatorship). * Patients deprived of liberty by judicial or administrative decision. * Patients not speaking French and not accompanied by a translator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of residual clinical samples successfully collected, aliquoted, and stored with associated clinical and microbiological data | 36months (end of patient inclusion period) | Creation of a collection of residual biological samples (serum, plasma, urine, respiratory samples, CSF, biopsies, etc.) and associated clinical and microbiological data obtained during routine care |
Countries
France
Contacts
CONTACTThierry NAAS,, PhD
CONTACTSaoussen OUESLATI, PhD
Outcome results
None listed